Agile Therapeutics Inc. (NASDAQ:AGRX) shares fell 3.4% during mid-day trading on Tuesday . The company traded as low as $6.86 and last traded at $7.11, with a volume of 400,220 shares traded. The stock had previously closed at $7.36.

A number of brokerages have recently issued reports on AGRX. Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research report on Tuesday. Zacks Investment Research raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Tuesday, May 10th. FBR & Co reaffirmed a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $15.00.

The company’s market capitalization is $200.40 million. The company has a 50 day moving average price of $7.11 and a 200-day moving average price of $6.62.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.29). On average, equities analysts anticipate that Agile Therapeutics Inc. will post ($1.24) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP raised its stake in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned approximately 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent SEC filing.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.